Orbimed Advisors LLC X4 Pharmaceuticals, Inc Transaction History
Orbimed Advisors LLC
- $3.21 Billion
- Q1 2025
A detailed history of Orbimed Advisors LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,776,515 shares of XFOR stock, worth $10 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
6,776,515
Previous 7,133,515
5.0%
Holding current value
$10 Million
Previous $5.49 Million
70.39%
% of portfolio
0.05%
Previous 0.15%
Shares
8 transactions
Others Institutions Holding XFOR
# of Institutions
95Shares Held
97.9MCall Options Held
500KPut Options Held
20.4K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$25 Million1.36% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$22.2 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$15.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.07MShares$11.9 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$10.8 Million1.22% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $102M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...